Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
BridgeBio Pharma Inc (BBIO)
NASDAQ:BBIO
Holding BBIO?
Track your performance easily
BBIO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$21.62 - $41.04
Previous Close$28.85
Volume1.46M
Average Volume (3M)1.96M
Market Cap
$5.34B
Enterprise Value$5.53B
Total Cash (Recent Filing)$266.32M
Total Debt (Recent Filing)$446.65M
Price to Earnings (P/E)―
Beta1.17
Next Earnings
Feb 20, 2025EPS Estimate
-$1.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.41
Shares Outstanding188,989,802
10 Day Avg. Volume1,067,964
30 Day Avg. Volume1,957,551
Standard Deviation0.24
R-Squared0.06
Alpha0.00910
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)-4.43
Price to Sales (P/S)24.53
Price to Cash Flow (P/CF)-7.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue25.40
Enterprise Value/Gross Profit806.78
Enterprise Value/Ebitda-15.17
Forecast
1Y Price Target
$49.54Price Target Upside71.72% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
BridgeBio Pharma News
Bulls Say, Bears Say
Bulls Say
Clinical OutcomesAcoramidis showed clear benefits on cardiovascular outcomes, significantly reducing cardiovascular-related hospitalization, improving survival, and preserving quality of life for patients.
Market StrategyAcoramidis' pricing is potentially attractive to payers as it is lower compared to Tafamidis, which could enhance its market appeal and acceptance.
Regulatory ApprovalFDA approved acoramidis (Attruby) in adult ATTR-CM patients ahead of its PDUFA action date, providing a significant boost to the company's market presence.
Bears Say
Competitive LandscapeA couple of RNA therapies and a gene editing approach are slated to compete against the TTR stabilizers, making it challenging for Attruby to differentiate early in its launch.
Financial HealthMessy financials add further risk, with a cash position of $478M and significant debt obligations, including $1.3B in converts due for refinancing.
Financial PerformanceThe stock has been roughly range bound due to a lack of catalysts clear enough to lift overhangs that have weighed on the stock.
---
Ownership Overview
20.77% Insiders
15.70% Mutual Funds
0.02% Other Institutional Investors
49.83% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BBIO FAQ
What was BridgeBio Pharma Inc’s price range in the past 12 months?
BridgeBio Pharma Inc lowest stock price was $21.62 and its highest was $41.04 in the past 12 months.
What is BridgeBio Pharma Inc’s market cap?
Currently, no data Available
When is BridgeBio Pharma Inc’s upcoming earnings report date?
BridgeBio Pharma Inc’s upcoming earnings report date is Feb 20, 2025 which is in 43 days.
How were BridgeBio Pharma Inc’s earnings last quarter?
BridgeBio Pharma Inc released its earnings results on Nov 12, 2024. The company reported -$0.86 earnings per share for the quarter, beating the consensus estimate of -$1.003 by $0.143.
Is BridgeBio Pharma Inc overvalued?
According to Wall Street analysts BridgeBio Pharma Inc’s price is currently Undervalued.
Does BridgeBio Pharma Inc pay dividends?
BridgeBio Pharma Inc does not currently pay dividends.
What is BridgeBio Pharma Inc’s EPS estimate?
BridgeBio Pharma Inc’s EPS estimate is -$1.13.
How many shares outstanding does BridgeBio Pharma Inc have?
BridgeBio Pharma Inc has 188,989,800 shares outstanding.
What happened to BridgeBio Pharma Inc’s price movement after its last earnings report?
BridgeBio Pharma Inc reported an EPS of -$0.86 in its last earnings report, beating expectations of -$1.003. Following the earnings report the stock price went down -5.743%.
Which hedge fund is a major shareholder of BridgeBio Pharma Inc?
Among the largest hedge funds holding BridgeBio Pharma Inc’s share is Viking Global Investors LP. It holds BridgeBio Pharma Inc’s shares valued at 640M.
---
BridgeBio Pharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$49.54 (71.72% Upside)
$49.54 (71.72% Upside)
Blogger Sentiment
Bullish
BBIO Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 5.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days <0.1%
Last 30 Days ▲ 2.5%
Last 30 Days ▲ 2.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-25.01%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
1.52%
Trailing 12-Months
Company Description
BridgeBio Pharma Inc
BridgeBio Pharma, Inc. engages in developing transformative medicines to treat patients who suffer from mendelian diseases. Its pipeline of 15 development programs includes product candidates from early discovery to late-stage development. The firm develops BBP-265, an oral small molecule transthyretin for the treatment of TTR amyloidosis, including cardiomyopathy and polyneuropathy manifestations; infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor for the treatment of FGFR-driven cancers and in preclinical development for the treatment of achondroplasia; and BBP-631, a preclinical adeno-associated virus, gene transfer product candidate, for the treatment of congenital adrenal hyperplasia caused by 21OHD. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly and Neil Kumar on May 17, 2019 and is headquartered in Palo Alto, CA.
---
BBIO Stock 12 Month Forecast
Average Price Target
$49.54
▲(71.72% Upside)
Technical Analysis
Best Analysts Covering BBIO
1 Year
1 Year Success Rate
10/14 ratings generated profit
1 Year Average Return
+22.54%
reiterated a buy rating last month
Copying Tyler Van Buren's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +22.54% per trade.
---